Madrigal Pharmaceuticals' Rezdiffra had a strong launch with $103.3M in Q4 sales and solid liquidity. See why I have a ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Altimmune's pemvidutide shows promise in treating MASH and obesity, with upcoming Phase 2b results poised to shape its market ...

Rare Disease Day, an annual gathering hosted by the FDA and National Institutes of Health, was postponed. Medicare spending on 10 diabetes drugs, including popular GLP-1s, more than quadrupled over a ...